Filtered By:
Condition: Atrial Fibrillation
Drug: Insulin

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 49 results found since Jan 2013.

Heartbeat: Highlights from this issue
Prevention of atrial fibrillation (AF) is an urgent unmet clinical need given its association with a higher risk of stroke, heart failure and death. Known risk factors for AF include age, hypertension, body mass index and diabetes as well as markers of systemic inflammation; all of which likely contribute to the high prevalence of this dysrhythmia in our aging, increasingly obese, population. However, there currently are no established biomarkers to help in assessment of AF risk. Adiponectin is an adipocyte-generated hormone with lower levels seen with increased adiposity. Adiponectin has insulin sensitizing, anti-inflamma...
Source: Heart - August 12, 2015 Category: Cardiology Authors: Otto, C. M. Tags: Drugs: cardiovascular system, Hypertension, Epidemiology, Tobacco use Heartbeat Source Type: research

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Publication date: Available online 11 August 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, John J V McMurray, June Ye Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes. Methods We did a meta-analysis of eight phase 3 trials and one phase 2b trial in which patients wer...
Source: The Lancet Diabetes and Endocrinology - August 12, 2015 Category: Endocrinology Source Type: research

Safety and efficacy of glucose-insulin-potassium treatment in coronary artery bypass graft surgery and percutaneous coronary intervention
The purpose of this meta-analysis was to evaluate protective effects of glucose–insulin–potassium (GIK) on outcomes after coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). We systematically searched Medline/Pubmed, Elsevier, Embase, Web of Knowledge and Google Scholar. A total of 1206 studies were retrieved during the extensive literature search of all major databases; however, 38 trials reporting the end-point of interest were selected. We performed a pooled analysis of outcomes following PCI: incidence of cardiac arrest [odds ratio (OR) of 0.91; 95% confidence interval (CI): ...
Source: Interactive CardioVascular and Thoracic Surgery - October 19, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Ali-Hassan-Sayegh, S., Mirhosseini, S. J., Zeriouh, M., Dehghan, A. M., Shahidzadeh, A., Karimi-Bondarabadi, A. A., Sabashnikov, A., Popov, A.-F. Tags: Congestive Heart Failure Adult Cardiac Source Type: research

Gender Discrepancy in Diabetic Patients Hospitalized With Heart Failure: Does Age Matter?
Conclusions: In DHF, female gender is characterized by having a high prevalence of metabolic syndrome components. Also, females are more likely to have better Left ventricular ejection fraction but less likely to receive cardiovascular evidence based medications. There is no significant difference in the overall hospital mortality between both genders, however, in the younger age; males have a significantly higher mortality.
Source: Critical Pathways in Cardiology - August 2, 2016 Category: Cardiology Tags: Original Studies Source Type: research

Uric acid and cardiovascular disease.
Abstract Uric acid (UA) is an end product of purine metabolism in humans and great apes. UA acts as an antioxidant and it accounts for 50% of the total antioxidant capacity of biological fluids in humans. When present in cytoplasm of the cells or in acidic/hydrophobic milieu in atherosclerotic plaques, UA converts into a pro-oxidant agent and promotes oxidative stress and through this mechanism participates in the pathophysiology of human disease including cardiovascular disease (CVD). Most epidemiological studies but not all of them suggested the existence of an association between elevated serum UA level and CVD...
Source: International Journal of Clinical Chemistry - May 24, 2018 Category: Chemistry Authors: Ndrepepa G Tags: Clin Chim Acta Source Type: research

Uric acid and cardiovascular disease
Publication date: September 2018 Source:Clinica Chimica Acta, Volume 484 Author(s): Gjin Ndrepepa Uric acid (UA) is an end product of purine metabolism in humans and great apes. UA acts as an antioxidant and it accounts for 50% of the total antioxidant capacity of biological fluids in humans. When present in cytoplasm of the cells or in acidic/hydrophobic milieu in atherosclerotic plaques, UA converts into a pro-oxidant agent and promotes oxidative stress and through this mechanism participates in the pathophysiology of human disease including cardiovascular disease (CVD). Most epidemiological studies but not all of them ...
Source: Clinica Chimica Acta - June 2, 2018 Category: Laboratory Medicine Source Type: research

Relation between high sensitivity c-reactive protein(hs-CRP) and thromboembolic risk markers assessed by echocardiography in patients with non-valvular atrial fibrillation(NVAF)
ConclusionHigh-sensitivity C-reactive protein( hs-CRP) ≥4.5 mg/dl level is suggested as inflammatory marker to predict the risk of thromboembolism in patients with non-valvular AF.
Source: Journal of Indian College of Cardiology - November 27, 2018 Category: Cardiology Source Type: research

Using wearable devices in clinical trials
Brandy Chittester, chief of clinical operations, IMARC Globally, more than 325 million people own wearable, connected devices, and more than 2.5 billion own smartphones. Using wearable devices in clinical trials can bring huge benefits, however, there are also concerns. Here’s a look at how researchers are using wearable devices — and what you should consider before using them in your own research. How wearable devices are advancing medicine Right now, ClinicalTrials.gov, a global database of clinical trials, lists nearly 200 trials with “wearable devices” or “wearable technology” in the description. This in...
Source: Mass Device - March 12, 2019 Category: Medical Devices Authors: Danielle Kirsh Tags: Blog IMARC Source Type: news

Atrial Transcriptional Profiles of Molecular Targets Mediating Electrophysiological Function in Aging and Pgc-1 β Deficient Murine Hearts
Conclusion: These findings limit the possible roles of gene transcriptional changes in previously reported age-dependent pro-arrhythmic electrophysiologial changes observed in Pgc-1β-/- atria to an altered Ca2+-ATPase (Atp2a2) expression. This directly parallels previously reported arrhythmic mechanism associated with p21-activated kinase type 1 deficiency. This could add to contributions from the direct physiological outcomes of mitochondrial dysfunction, whether through reactive oxygen species (ROS) production or altered Ca2+ homeostasis. Introduction Atrial arrhythmias constitute a major public health pro...
Source: Frontiers in Physiology - April 23, 2019 Category: Physiology Source Type: research

The relation between echocardiographic epicardial fat thickness and mitral annular calcification
Conclusion: We showed that EFT was significantly elevated in patients with MAC and it was positively correlated with MAC.Keywords: mitral annular calcification, epicardial fat thickness, cardiovascular risk.
Source: African Health Sciences - April 17, 2019 Category: African Health Source Type: research

Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
ConclusionThe prevalence of CVD in patients with type 2 diabetes in clinical practice in Sweden was 28.3% during the study period, and it was 11.5% in the patients starting empagliflozin treatment. Patients of the latter cohort were, however, younger, more obese, and more likely to have unsatisfactory glycemic control, requiring additional treatment. Overall, a large proportion of type 2 diabetes patients should be considered at high cardiovascular risk.FundingBoehringer Ingelheim AB, Sweden.
Source: Diabetes Therapy - May 13, 2019 Category: Endocrinology Source Type: research

Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes.
CONCLUSION: - These results suggest that NAFLD and significant LF (as assessed by FibroScan) are very commonly seen in T2DM outpatients with no known liver disease attending a secondary-care diabetes service, and that increased LF is associated with a greater proportion of chronic vascular complications, especially CKD. PMID: 31786361 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism - November 27, 2019 Category: Endocrinology Authors: Mantovani A, Turino T, Lando MG, Gjini K, Byrne CD, Zusi C, Ravaioli F, Colecchia A, Maffeis C, Salvagno G, Lippi G, Bonora E, Targher G Tags: Diabetes Metab Source Type: research

Hemichorea in ketotic hyperglycemia with hyperdense striatum mimicking hemorrhagic transformation in a patient using apixaban.
CONCLUSION: Diabetic striatopathy is a rare but treatable disorder and should be considered in patients with poorly controlled diabetes who present with hemichorea. PMID: 33307650 [PubMed - as supplied by publisher]
Source: Neuroendocrinology Letters - December 16, 2020 Category: Endocrinology Tags: Neuro Endocrinol Lett Source Type: research